RDUS Radius Health, Inc.

-3  -7%
Previous Close 38.38
Open 38.37
Price To book 5.39
Market Cap 1.54B
Shares 43,186,000
Volume 1,328,590
Short Ratio 11.22
Av. Daily Volume 753,890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 1H 2017.
Vasomotor symptoms
PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017.

Latest News

  1. 5 Stocks Insiders Love Right Now
  2. Is The Radius Health Inc (RDUS) Dip A Discount Opportunity?
  3. Falling Biotechs: Cara Reports Zero Sales, Ionis Downgraded
  4. Waltham-based Radius Health faces 3-month delay on drug approval
  5. RADIUS HEALTH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  6. Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC
  7. 5 FDA Decisions to Watch Out for in Mar 2017
  8. RADIUS HEALTH, INC. Financials
  9. 5 Small-Cap Biotech Stocks to Buy in March
  10. Radius Health to Present at Cowen and Company 37th Annual Health Care Conference
  11. RADIUS HEALTH, INC. Files SEC form 10-K, Annual Report
  12. Radius Health (RDUS) Posts Wider Loss in Q4
  13. Edited Transcript of RDUS earnings conference call or presentation 23-Feb-17 9:30pm GMT
  14. Radius Health reports 4Q loss
  15. Radius Health reports 4Q loss
  16. RADIUS HEALTH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
  17. Radius Health Reports Fourth Quarter and Full Year 2016 Financial and Operating Results
  18. Q4 2016 Radius Health Inc Earnings Release - Time Not Supplied
  19. Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
  20. Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis